Literature DB >> 6252833

Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.

R Wise, S Baker, R Livingston.   

Abstract

The pharmacokinetics of cefotaxime and moxalactam were compared in six healthy male volunteers aftr the administration of 1-g doses intravenously. Penetration of the compounds into tissue fluid was studied in cantharides-induced blisters. Both serum and tissue fluid levels of moxalactam were higher than those of cefotaxime. The elimination half-life of cefotaxime was 1.2 h, and that of moxalactam was 2.85 h. On the average, 50.5% of cefotaxime and 87.5% of moxalactam were recovered in the urine in 24 h.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6252833      PMCID: PMC284007          DOI: 10.1128/AAC.18.3.369

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  [Cefazolin, a new broad-spectrum antibiotic (author's transl)].

Authors:  C Simon; V Malerczyk; E Brahmstaedt; W Toeller
Journal:  Dtsch Med Wochenschr       Date:  1973-12-21       Impact factor: 0.628

2.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

3.  HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.

Authors:  R Wise; T Rollason; M Logan; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

4.  Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.

Authors:  R Wise; P J Wills; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

5.  LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

6.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

  6 in total
  17 in total

1.  Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: in vitro pharmacodynamic simulation.

Authors:  I P Balcabao; L Aguilar; M Martín; Y García; R Dal-Ré; J Prieto
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

2.  Third generation cephalosporins in the parenteral to oral switch.

Authors:  D Rimmer
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

3.  Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

Authors:  K S Israel; H R Black; G L Brier; J D Wolny; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

4.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

5.  Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.

Authors:  P J McNamara; K Stoeckel; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

7.  The pharmacokinetics of new cephalosporins: significance in clinical practice.

Authors:  H C Neu
Journal:  Bull N Y Acad Med       Date:  1984-05

8.  Peritoneal absorption of moxalactam.

Authors:  N M Stephens; N O Kronfol; B J Kline; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

9.  Comparative pharmacokinetics of ceftazidime and moxalactam.

Authors:  T B Tjandramaga; A Van Hecken; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

10.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.